Ethylene vinylacetate polymer (EVA) has been used for many years to fabricate controlled-release polymeric implant devices with which drugs of high or low molecular weight compounds could be delivered with zero-order kinetics. However, because the known fabrication methods such as solvent evaporation, casting and possible shrinkage are not sufficiently controllable we have now developed the microextrusion method with which even small amount of clinically important and expensive drugs can be incorporated into EVA with high reproducibility. We show here that devices produced by the microextrusion method allows for a controlled delivery of several neurotoxic and neurotherapeutic compounds such as alpha-methyl-p-tyrosine, diazepam, quinolinic acid, and phencyclidine. Each substance is slowly released from the polymer, as evidenced by spectrophotometric data, for up to 120 days at daily rates varying from 18.4 mg of phencyclidine to 97.6 mg/day of diazepam. Thus, microextrusion is a valuable method for fabricating controlled-release polymers in which small amounts of scarce drugs can be incorporated. Another advantage of the current procedure is that polymers can be fabricated with very little amount of solvent.
Introduction
Ethylene vinylacetate (EVA) co-polymer has been used for many years as a non-inflammatory, nonbiodegradable material for the controlled release of proteins (Silberstein and Daniel, 1987) and other macromolecules such as growth factors (Langer and Folkman, 1976; Rhine et al., 1980; Politis, 1986) and small molecular weight compounds such as L-dopa (Sabel et al., 1990a) , dopamine or haloperidol (Koehler et al., 1994) . EVA is capable of releasing substances for extended periods of time both in vitro and in vivo (Sabel et al., 1990b) of times ranging from days to years, and in the area of neuroscience research EVA implants have been used for either intracerebral or subcutaneous implantation (Langer and Wise, 1984; Politis, 1985; During et al., 1989; Freese et al., 1989; Cline and Constantine-Paton, 1990; Sabel et al., 1990a,b; Koehler et al., 1994; Smith et al., 1995) . One of the problems, however, is that the fabrication of polymeric implants requires a relatively large amount of drug both in the solvent casting and in the sintering methods (Siegel and Langer, 1984) . Because many compounds, such as neuroactive drugs are only available in small amounts it may be impossible or extremely expensive to incorporate them using conventional methods. It is therefore desirable to have a fabrication method available whereby such substances can be incorporated into the EVA-polymer with essentially no material waste during the production process. We developed the microextrusion method to allow for the fabrication of very small implants that are useful for the delivery of scarce and valuable substances.
Microextrusion also provides a standard fabrication method which requires only small amounts of solvent and they display no shrinkage and little variability in release rate. The feasibility of the microextrusion method was evaluated with four different neuroactive drugs: (a) diazepam, a benzodiazepine, which is used as a tranquilizer to treat general anxiety disorders (Frazer and Hensler, 1994) , (b) alpha-methyl-p-tyrosine, a tyrosine hydroxylase inhibitor (Hallman and Jonsson, 1984) , (c) phencyclidine (PCP), an NMDA antagonist (Piercy and Ray, 1988) , and (d) quinolinic acid (QA), an excitotoxic NMDA receptor agonist (Beal et al., 1991) .
Materials and methods
Ethylene vinylacetate co-polymer with 40% vinylacetate content (EVA 40W; DuPont Co., Wilmington, DE 19898, USA) was purified thoroughly with acetone distillation. For microextrusion preparation, EVA was placed in a glass beaker, dissolved in dichloromethane (Fluka Chemica) at a 1:4 w/w ratio and placed overnight in a laboratory vacuum oven at room temperature and a pressure of 150 mbar to ensure proper liquidity of the EVA. After cooling down the EVA to room temperature, the drug was added to the EVA/ dichloromethane solution along with 0.2 g of dichloromethane. This was mixed thoroughly to ensure even suspension. The following drugs were thus incorporated (w/w percent loading in parentheses): diazepam (30%; Hoffman-LaRoche, Grenzach-Wyhlen; Germany), alpha-methyl-p-tyrosine (30%; RBI, Koeln, Germany), phencyclidine (30%; Sigma, St. Louis, MO, USA), or quinolinic acid (50%; Sigma). The listed drug incorporations based on total weight. The viscoelastic suspension was then poured into a small petri dish in which a one-sided Teflon filter paper (Schleicher and Schuell, GmbH, Dassel, Germany, Teflon side up) had been placed before. The Teflon filter paper with the polymer/drug mixture was then removed from the petri dish, weighed on a standard laboratory scale and subsequently placed into a partial vacuum (150 mbar) at room temperature to completely evaporate the dichloromethane. Weight measurements were repeated daily and when the polymer weight was found to be constant (usually after about 1 week), full evaporation of the dichloromethane was assumed. The polymer containing the drug was then placed into a test tube and prepared for molding. The apparatus for molding the polymers consisted of a vacuum pump (RZ 2, Vacuubrand, Inc.) and a magnetic stirrer/hot plate (PT 100 from IKA, Inc.). The pump was connected to a series of rubber tubing each with successively smaller diameters assembled in such a manner that a 1.0 mm diameter Teflon tube (PTFE-Chemieschlauch, Reichelt Chemie Technik GmbH and Co., Heidelberg, Germany) could be inserted into the final piece of tubing while still maintaining the vacuum. The test tube containing the dried polymer was lowered half way into a beaker containing 90°C pike oil which was stirred. By inserting the test-tube into the pike oil bath the polymer was then heated to 85-90°C and drawn up through the Teflon tube by applying the vacuum. After the polymer was drawn up approximately 5 mm into the tube, the vacuum was inactivated and the Teflon tube withdrawn (Fig. 1) . After cooling to room temperature, the cylindrical polymer was cut out of the Teflon tubing, ready for subsequent implantation. The advantage of this fabrication method is that polymers can be shaped into stable forms which do not change their geometry after fabrication, which is generally a problem when evaporation of the dichloromethane occurs after the polymeric device is moulded into the final shape. To evaluate the release kinetics from polymers fabricated in such a fashion in vitro, the polymers were first weighed and subsequently placed into separate glass jars containing 10 ml of 10 mM phosphate buffered saline (PBS, pH 7.4). In each glass jar containing PBS was taken one polymer with an average weight of 8.0 mg. These jars were left overnight at room temperature and the solution was stirred about 10 min before the sample for the release experiments was taken. To determine drug release, a spectrophotometric analysis of the bathing solution was performed in regular 24-h intervals and the polymer devices were placed in fresh PBS solution thereafter. A spectrophotometer (DU 650, Beckman, Inc., USA) was used to scan the wavelengths of each substance (1.0 mg substance/10 ml PBS) and a single absorption was selected for each drug. A calibration curve for each drug was established using the following wavelengths: diazepam (229 nm), alphamethyl-p-tyrosine (223 nm), phencyclidine (261 nm), and quinolinic acid (267 nm). 
Results
The microextrusion procedure proved to be a reliable method for all drugs studied. The devices had a predictable rod shape with very little variability in size and weight. The determination of drug release in vitro revealed the following results: release of diazepam (n= 5) was found to be nearly linear with a total of 2.05 mg or 97.6 mg/daily over a 21-day period (Fig. 2) . Alphamethyl-p-tyrosine (n =5) was released for 28 days with a total release rate of 2.41 mg (86.1 mg per day) (Fig. 3) . The release of alpha-methyl-p-tyrosine was constant for up to 10 days, but thereafter it continued to release at a slower rate during the remainder of the study. Phencyclidine was released for as long as 120 days with a total release of 2.21 mg, which corresponds to 18.4 mg per day (n = 6) (Fig. 4) . The release of phencyclidine was found to be linear for up to 30 days, where release continued at a decreasing rate for the remainder of the experiment. Both substances, alpha-methyl-p-tyrosine and phencyclidine gave a hyperbolic function for the release kinetics. Quinolinic acid (QA, n = 5) was released for at least 58 days, yielding a total release of 0.979 mg. As seen in Fig. 5 , the 50% QA loaded EVA released steadily during the first 25 days while a slightly decreased release rate was observed thereafter. The release kinetics can be described as curvilinear function.
Discussion
The results of this study indicate that the microextrusion method of producing EVA polymers provides a convenient and efficient way to fabricate small uniformly sized polymers to incorporate scarce and expensive drugs. The evaporation of the dichloromethane solvent before moulding the polymer eliminates deformation and shrinkage of the polymer which normally occurs after solvent casting. The EVA polymers produced via the microextrusion method proved to be effective for slowly releasing a variety of experimental and clinical drugs. Microextruded EVA allows for a controlled release of diazepam (MW 289.8), , phencyclidine (MW 284.9) and quinolinic acid (MW 167.1). In previous studies, EVA has been incorporated with higher molecular weight compounds such as growth factors and proteins. However, microextrusion may not be useful for the preparation of polymers containing these substances, as the heating of the polymer/drug mixture may cause denaturing of the substance. Further research is needed to determine the viability of this method for preparing polymers that deliver proteins.
The results of this study also suggest that the release rate of the drug from the polymer may be a function of the hydrophilicity of the drug used. This would explain why the release of diazepam is much slower than the release of the less hydrophilic alpha-methyl-p-tyrosine. The release of drug particles from the polymer surface is initiated by contact with the polar water molecules. This creates pores in the polymers that are filled by water which in turn extracts more drug particles. This process continues until all of the drug particles that are in contact with the water-filled pores have been extracted.
In conclusion, the importance of this new easy and safe method for polymer preparation is that it opens up new uses for EVA in the neurosciences.
